Neuromyelitis Optica Spectrum Disorder
📧 Sign up to get email alerts when something new happens for Neuromyelitis Optica Spectrum Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-04Clinical Trial Update: Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
Clinical trial registry update for the PRISMA pregnancy registry, collecting data on infants and maternal serum/milk analysis to assess expo…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: High Frequency Impulse Therapy for Neuropathic Pain in NMOSD [Phase 2]
The update reports the completion of a Phase 2 trial evaluating High Frequency Impulse Therapy for neuropathic pain in Neuromyelitis Optica …
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD [NA]
This clinical trial evaluates the impact of a Structured Wellness Behavioral Intervention on quality of life for people with Neuromyelitis O…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD [NA]
Clinical trial update on a digital tool for unsupervised self-assessment in neuromyelitis optica spectrum disorder; the study is currently r…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Meningococcal Vaccination in Patients on Complement Inhibitors
This clinical trial update concerns meningococcal vaccination in patients treated with complement inhibitors. It includes patients with gene…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]
Clinical trial update notes safety and efficacy evaluation of daratumumab in patients with anti-AQP4 antibody positive neuromyelitis optica …
-
FDA approval · 2025-03-12FDA Approved: EPYSQLI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for EPYSQLI (eculizumab-aagh), a biosimilar to eculizumab.
-
CLINICAL_TRIALS research · 2025-01-27Clinical Trial Update: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating B001 Injection for Neuromyelitis Optica Spectrum Disorders is currently recruiting. The sponsor listed…
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention [Phase 4]
Clinical trial update reporting results from a Phase 4 study of satralizumab in neuromyelitis optica spectrum disorder, with the trial termi…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Comparative Study on AQP4 Antibody Detection Methods
This clinical trial update describes a comparative study of AQP4 antibody detection methods in NMOSD, sponsored by the First Affiliated Hosp…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: ACT with NMOSD Patients and Caregivers Pilot Study [NA]
A completed pilot clinical trial evaluating ACT with Neuromyelitis Optica Spectrum Disorder patients and caregivers; sponsored by Thomas Jef…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
Phase 3 trial evaluating the safety and efficacy of satralizumab in Neuromyelitis Optica Spectrum Disorder has completed and results have be…
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
Clinical and imaging cohort study in China (CLUE) recruiting to collect data on neuroinflammatory diseases, including Neuromyelitis optica s…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Swiss-Ped-IBrainD is a pediatric brain inflammation registry sponsored by the University of Bern and is currently recruiting, enrolling chil…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety of JYP0061 in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) is cu…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Biomarkers in Autoimmune Disease of Nervous System
A Tongji Hospital clinical trial is recruiting to study biomarkers in autoimmune diseases of the nervous system, including Neuromyelitis Opt…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD [Phase 1]
A Phase 1 clinical trial sponsored by Bioray Laboratories is evaluating universal BCMA-targeting CAR-T cells for refractory neuromyelitis op…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System [EARLY_Phase 1]
An early-phase clinical trial is investigating CT103A cell therapy for relapsed/refractory antibody-associated inflammatory diseases of the …
-
FDA approval · 2024-10-23FDA Approved: BKEMV — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for BKEMV (eculizumab-aeeB) from Amgen, updating its labeling and indications for this eculizuma…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders [Phase 1, Phase 2]
This clinical trial update reports Phase 1/2 data on the efficacy and safety of belimumab in neuromyelitis optica spectrum disorder. The stu…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the efficacy and safety of baricitinib in neuromyelitis optica spectrum disorder, currently recruiting…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2, Phase 3]
A pediatric Phase 2/3 trial of eculizumab for relapsing neuromyelitis optica spectrum disorder was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2024-09-20Clinical Trial Update: Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD) [NA]
This clinical trial is evaluating the efficacy and safety of Calculus Bovis Sativus (CBS) for idiopathic inflammatory demyelinating diseases…
-
FDA approval · 2024-09-19FDA Approved: SOLIRIS — Supplemental Application (Alexion Pharmaceuticals Inc.)
The FDA approved a supplemental application for SOLIRIS (eculizumab) filed by Alexion Pharmaceuticals, resulting in updated labeling that ma…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
A clinical trial registration indicates ongoing recruitment for Inebilizumab in acute Neuromyelitis Optica Spectrum Disorder.